Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 7945.13%.

  • Cartesian Therapeutics' EBITDA Margin fell 16924200.0% to 7945.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 4395.97%, marking a year-over-year decrease of 38852700.0%. This contributed to the annual value of 199.02% for FY2024, which is 6460500.0% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' EBITDA Margin stood at 7945.13%, which was down 16924200.0% from 5334.9% recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' EBITDA Margin peaked at 5334.9% during Q2 2025, and registered a low of 7945.13% during Q3 2025.
  • Its 5-year average for EBITDA Margin is 686.66%, with a median of 73.26% in 2021.
  • In the last 5 years, Cartesian Therapeutics' EBITDA Margin plummeted by -61149900bps in 2024 and then surged by 52934900bps in 2025.
  • Over the past 5 years, Cartesian Therapeutics' EBITDA Margin (Quarter) stood at 40.86% in 2021, then decreased by -15bps to 34.92% in 2022, then crashed by -6254bps to 2149.07% in 2023, then surged by 163bps to 1352.83% in 2024, then plummeted by -687bps to 7945.13% in 2025.
  • Its last three reported values are 7945.13% in Q3 2025, 5334.9% for Q2 2025, and 1607.09% during Q1 2025.